Navigation Links
Sanofi-aventis Announces Good First-quarter 2009 Performance
Date:4/29/2009

ral expenses were 2.9% lower (5.6% at constant exchange rates), at euro 1,732 million. The ratio of selling and general expenses to net sales was 24.4%, versus 25.7% for the first quarter of 2008, due to the ongoing measures taken by sanofi-aventis to adapt to market conditions and the end of the commercialization of Copaxone(R) in North America.

Other current operating income and expenses showed net income of euro 148 million, against net income of euro 104 million in the first quarter of 2008. The 2009 figure includes the payment by Teva of a fee equal to 25% of the North American sales of Copaxone(R).

Operating income - current(1) was up 14.9% at euro 2,898 million. At constant exchange rate, the growth rate was 8.6%. The ratio of operating income - current to net sales improved by 4.4 points to 40.8%.

Net financial expenses were euro 44 million, against euro 17 million for the first quarter of 2008 (which included a gain on currency hedging). Interest expense on debt was euro 26 million, lower than the 2008 first-quarter figure of euro 44 million. Sanofi-aventis acquired Zentiva shares related to the public offer on March 11, 2009 for euro 1,197 million.

The effective tax rate was down 0.6 of a point at 29%, and was in line with the 2008 full-year figure.

The share of profits from associates was up 16.7% at euro 273 million. The share of after-tax profits from territories managed by BMS under the Plavix(R) and Avapro(R) alliance was 28.1% higher at euro 187 million, due to a good performance from Plavix(R) in the United States and a favorable dollar effect.

Minority interests increased by 5.2% to euro 121 million. The share of pre-tax profits paid to BMS from territories managed by sanofi-aventis rose by 3.6% to euro 115 million.

Adjusted net income excluding selected items(1) was euro
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Sanofi-Aventis and Roche/Chugais Drugs Will Dominate the Indian Colorectal Cancer Drug Market Through 2013
2. Sanofi-aventis Affirms Its Commitment to Partnering with Local Communities to Improve Hispanic and African American Health
3. Apidra(R) SoloSTAR(R), the Easy-to-Use Insulin Delivery Device from sanofi-aventis, Now Available in the United States
4. Paul Chew Appointed to sanofi-aventis U.S. Chief Science Officer/Chief Medical Officer
5. Sanofi-aventis Partners with the Hispanic Community in Miami to Increase Health Awareness, Access to Resources and Help Improve Patient Care
6. Sanofi-aventis Partners with the Hispanic Community in San Antonio to Increase Health Awareness, Access to Resources and Help Improve Patient Care
7. Sanofi-aventis Delivers 2008 Results Above Guidance
8. Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care
9. Sanofi-aventis Partners with the African American Community in Memphis to Increase Health Awareness, Access to Resources and Help Improve Patient Care
10. Sanofi-aventis U.S. Announces Increased Access to Drugs for Low Income Patients Through Expanded PAP Programs
11. Sanofi-aventis Partners with the African American Community in Baltimore to Increase Health Awareness, Access to Resources and Help Improve Patient Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... Clinical trial report, “Edema Global Clinical ... clinical trial scenario. This report provides elemental information and ... includes an overview of the trial numbers and their ... across the globe. The databook offers a preliminary coverage ... prominence of the sponsors and also provides briefing pertaining ...
(Date:9/18/2014)... London. (PRWEB) September 18, 2014 CD-adapco, ... Aided Engineering software, today announced its new partnership with ... utilizing the CD-adapco simulation tool, STAR-CCM+® in the design ... announced its participation in the 35th America’s Cup taking ... edition of the America’s Cup is sustainability, the set ...
(Date:9/18/2014)... This news release is available in German . ... at Technische Universitt Mnchen have won the ,International ... Hepatitis C Virus., As their prize, the scientists will ... the space station. The project involves crystallizing two proteins ... shuttle bringing these proteins to the International Space Station ...
(Date:9/18/2014)... According to a new market report published by Transparency ... Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020,” ... USD 77607.7 million in 2013 and is expected to grow ... reach an estimated value of USD 115474.9 million in 2020. ... at a rapid pace due to increasing prevalence of end ...
(Date:9/18/2014)... Norfolk, Virginia (PRWEB) September 18, 2014 ... in the START (Smart Teens Accepting Responsibility Today) Internship ... Stacie D. and Darcy C. describe the program as ... women had any idea about what they would be ... to get coffee, do food runs and other mindless ...
Breaking Medicine News(10 mins):Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 2Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 3Health News:Edema Therapeutics Clinical Trials Market 2014 Review Report Available at MarketOptimizer.org 4Health News:Ben Ainslie Racing Using STAR-CCM+ Simulation Software to Design 35th America’s Cup Racing Boat 2Health News:Hepatitis C virus proteins in space 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 2Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 3Health News:Dialysis Products and Services Market Expected to Reach USD 115.4 Billion Globally in 2020 4Health News:ARDX Internship Helps Students to START on the Right Business Path 2Health News:ARDX Internship Helps Students to START on the Right Business Path 3Health News:ARDX Internship Helps Students to START on the Right Business Path 4
... Hundreds ... HCG and how can it help us? , ... May 13, 2010 -- HCG, or human chorionic gonadotropin, is a natural hormone that is found in ... as energy for both the mom and her developing baby. , , , , ,Now, thanks ...
... ... cut from the USDA-NIFA budget, causing a concern among scientists about how urgent, near-term challenges ... (PRWEB) ... appeal to the U.S. Department of Agriculture (USDA) National Institute of Food and Agriculture (NIFA) ...
... ... InterHealth Canada,s three new Turks and Caicos clinical facilities allowing the islands to provide ... ... Telemedicine Inc, the worldwide leading supplier of telemedicine technology , devices, and application ...
... an increased risk of blindness, yet nearly half of the ... annual eye exam to detect possible problems. But ... problems related to diabetes can help meet the screening need, ... compared the ability of two sets of computer programs to ...
... ... House Appropriations Subcommittee to increase funding to federal programs supporting Meharry and the nation,s ... ... M.D., MPH, MBA, MACP, President & Chief Executive Officer of Meharry Medical ...
... can cause trouble, experts say , WEDNESDAY, May 12 (HealthDay ... implant and maintain could make life better for people who ... , A defibrillator delivers an electric shock to restart a ... implanted in Americans each year. Current models require careful surgery ...
Cached Medicine News:Health News:All About the HCG Drops Diet Program—What it is and Why it Works 2Health News:WSSA Issues Strong Appeal to USDA for Restoration of Funding for Weed Science 2Health News:WSSA Issues Strong Appeal to USDA for Restoration of Funding for Weed Science 3Health News:WSSA Issues Strong Appeal to USDA for Restoration of Funding for Weed Science 4Health News:AMD Global Telemedicine Inc. Chosen by InterHealth Canada as the Telemedicine Solutions Provider for Turks and Caicos Hospital Project 2Health News:AMD Global Telemedicine Inc. Chosen by InterHealth Canada as the Telemedicine Solutions Provider for Turks and Caicos Hospital Project 3Health News:Computers can effectively detect diabetes-related eye problems 2Health News:Computers can effectively detect diabetes-related eye problems 3Health News:Meharry Medical College President Testifies Before the U.S. House of Representatives 2Health News:Meharry Medical College President Testifies Before the U.S. House of Representatives 3Health News:New Implanted Defibrillator May Be Simpler, Safer 2Health News:New Implanted Defibrillator May Be Simpler, Safer 3
(Date:9/18/2014)... , Sept. 18, 2014 MiMedx Group, ... developer, processor and marketer of patent protected regenerative ... announced today that it has entered into a ... MiMedx will provide its dehydrated human amnion/chorion membrane ... non- exclusively on a private label basis. ...
(Date:9/18/2014)... 18, 2014  Halozyme Therapeutics, Inc. (NASDAQ: ... Food and Drug Administration (FDA) has removed the ... PEGPH20 in SWOG,s ongoing Phase 1b/2 clinical trial ... investigational drug PEGPH20 (PEGylated Recombinant Human Hyaluronidase) in ... with metastatic pancreatic adenocarcinoma.  The study will resume ...
(Date:9/18/2014)... -- Relmada Therapeutics, Inc., (OTCQB: RLMD), a clinical-stage company ... announced today that it has appointed Mr. Christopher ... of Clinical Development. During his extensive career ... successful global clinical operations teams, in the US and ... development of numerous therapeutics and diagnostics across a broad ...
Breaking Medicine Technology:MiMedx Signs Distribution Agreement With Zimmer 2MiMedx Signs Distribution Agreement With Zimmer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 2SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 3SWOG To Resume Clinical Trial Of Halozyme's PEGPH20 In Combination With Modified FOLFIRINOX For Advanced Pancreatic Cancer 4Relmada Therapeutics, Inc. Appoints Christopher W. James As Senior Director of Clinical Development 2
... (ASX: PGL; Nasdaq: PGLA) today announced additional,data from the ... this,year. This data was presented at the 58th Annual ... Diseases in Boston, USA(1). As the Phase 2 ... data analysis described in this presentation was performed to,evaluate ...
... overall rate of sustained virologic response in ... long-acting interferons in ... Albuferon non-responder study presented at the, Annual Meeting of the American Association for the Study ... ...
Cached Medicine Technology:Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 2Progen Presents Additional Analysis of Data from PI-88 Phase 2 Liver Cancer Study at American Association for the Study of Liver Diseases 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 2Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 3Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 4Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 5Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy 6
... German Craftsmanship have produced the ... world. Ocutek now makes them ... of the coveted Meisterbrief certificate, ... are qualified to become Ocutek ...
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medtronic Ophthalmics offers a comprehensive selection of corneal trephine,blades and handles. Handcrafted, sharp, uniform blade edges promote a,symetrical and vertical cut of all corneal layers....
Medicine Products: